Contents

Current Cancer Drug Targets, Volume 5 - Number 1

Editorial [Hot Topic: MDM2 as a Cancer Therapeutic Target (Guest Editor: Ruiwen Zhang)]

, 5(1): 1 - 2

Ruiwen Zhang


DOI: 10.2174/1568009053332609




MDM2 is a Central Node in the p53 Pathway: 12 Years and Counting

, 5(1): 3 - 8

Gareth L. Bond, Wenwei Hu and Arnold J. Levine


DOI: 10.2174/1568009053332627




p53-Independent Activities of MDM2 and Their Relevance to Cancer Therapy

, 5(1): 9 - 20

Zhuo Zhang and Ruiwen Zhang


DOI: 10.2174/1568009053332618




MDM2 Splice Variants and Their Therapeutic Implications

, 5(1): 21 - 26

L. C. Harris


DOI: 10.2174/1568009053332654




MDM2 and Human Malignancies: Expression, Clinical Pathology, Prognostic Markers, and Implications for Chemotherapy

, 5(1): 27 - 41

Elizabeth Rayburn, Ruiwen Zhang, Jie He and Hui Wang


DOI: 10.2174/1568009053332636




Novel Antisense Anti-MDM2 Mixed-Backbone Oligonucleotides: Proof of Principle, In Vitro and In Vivo Activities, and Mechanisms

, 5(1): 43 - 49

Ruiwen Zhang, Hui Wang and Sudhir Agrawal


DOI: 10.2174/1568009053332663




Chemosensitization by Antisense Oligonucleotides Targeting MDM2

, 5(1): 51 - 56

Roberto Bianco, Fortunato Ciardiello and Giampaolo Tortora


DOI: 10.2174/1568009053332681




Small Molecule Antagonists of the MDM2 Oncoprotein as Anticancer Agents

, 5(1): 57 - 68

John K. Buolamwini, James Addo, Shantaram Kamath, Shivaputra Patil, Mason Mason and Marian Ores


DOI: 10.2174/1568009053332672




Author Index to Volume 4

, 5(1): 69 - 71

Bentham Science Publishers


DOI: 10.2174/1568009053332645




Subject Index to Volume 4

, 5(1): 73 - 84

Bentham Science Publishers


DOI: 10.2174/1568009053332690




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science